Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma Inc. announced that Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, has filed a petition with the USPTO challenging the validity of one of Ascletis’ U.S. patents. This patent, crucial for the development of Ascletis’ drug candidate ASC30, is under review, and Ascletis is committed to defending its intellectual property rights. The company continues its operations unaffected while monitoring the situation closely.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs, particularly in the area of GLP-1R agonists. The company leverages proprietary technologies to advance its drug candidates and holds various patents to protect its intellectual property.
Average Trading Volume: 6,406,266
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.35B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.